JKC 302, also known as an endothelin receptor (ETA) antagonist, is a chemical compound that selectively inhibits the action of endothelin-1 at the ETA receptor. This receptor is primarily involved in vasoconstriction and plays a significant role in various cardiovascular and renal pathologies. The compound's mechanism of action involves blocking the binding of endothelin-1, which can lead to vasodilation and a reduction in blood pressure. JKC 302 is characterized by its potential therapeutic applications in conditions such as pulmonary arterial hypertension and heart failure. The molecular structure of JKC 302 contributes to its specificity and efficacy as an antagonist, making it a subject of interest in pharmacological research. Additionally, its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are crucial for determining its suitability for clinical use. Overall, JKC 302 represents a promising avenue for the development of treatments targeting endothelin-related disorders.

jkc 302 endothelin receptor (eta)*antagonist

153982-38-8: JKC 302, also known as an endothelin receptor (ETA) antagonist, is a chemical compound that selectively inhibits the action of endothelin-1 at the ETA receptor. This receptor is primarily involved in vasoconstriction and plays a significant role in various cardiovascular and renal pathologies. The compound's mechanism of action involves blocking the binding of endothelin-1, which can lead to vasodilation and a reduction in blood pressure. JKC 302 is characterized by its potential therapeutic applications in conditions such as pulmonary arterial hypertension and heart failure. The molecular structure of JKC 302 contributes to its specificity and efficacy as an antagonist, making it a subject of interest in pharmacological research. Additionally, its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are crucial for determining its suitability for clinical use. Overall, JKC 302 represents a promising avenue for the development of treatments targeting endothelin-related disorders.

<p>Please enquire for more information about Cyclo(-D-Ser-Pro-D-Val-Leu-D-Trp) including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

CAS 153982-38-8

jkc 302 endothelin receptor (eta)*antagonist

Cyclo(-D-Ser-Pro-D-Val-Leu-D-Trp)

Ref: 3D-FC108865